221 related articles for article (PubMed ID: 16211238)
1. The tuberous sclerosis genes, TSC1 and TSC2, trigger different gene expression responses.
Rosner M; Freilinger A; Lubec G; Hengstschläger M
Int J Oncol; 2005 Nov; 27(5):1411-24. PubMed ID: 16211238
[TBL] [Abstract][Full Text] [Related]
2. The cellular response to ectopic overexpression of the tuberous sclerosis genes, TSC1 and TSC2: a proteomic approach.
Hengstschläger M; Rosner M; Fountoulakis M; Lubec G
Int J Oncol; 2005 Sep; 27(3):831-8. PubMed ID: 16077935
[TBL] [Abstract][Full Text] [Related]
3. Tuberous sclerosis genes regulate cellular 14-3-3 protein levels.
Hengstschläger M; Rosner M; Fountoulakis M; Lubec G
Biochem Biophys Res Commun; 2003 Dec; 312(3):676-83. PubMed ID: 14680818
[TBL] [Abstract][Full Text] [Related]
4. The expression of hamartin, the product of the TSC1 gene, in normal human tissues and in TSC1- and TSC2-linked angiomyolipomas.
Plank TL; Logginidou H; Klein-Szanto A; Henske EP
Mod Pathol; 1999 May; 12(5):539-45. PubMed ID: 10349994
[TBL] [Abstract][Full Text] [Related]
5. Proteins interacting with the tuberous sclerosis gene products.
Rosner M; Freilinger A; Hengstschläger M
Amino Acids; 2004 Oct; 27(2):119-28. PubMed ID: 15351877
[TBL] [Abstract][Full Text] [Related]
6. Tuberous sclerosis causing mutants of the TSC2 gene product affect proliferation and p27 expression.
Soucek T; Rosner M; Miloloza A; Kubista M; Cheadle JP; Sampson JR; Hengstschläger M
Oncogene; 2001 Aug; 20(35):4904-9. PubMed ID: 11521203
[TBL] [Abstract][Full Text] [Related]
7. The tuberous sclerosis genes and regulation of the cyclin-dependent kinase inhibitor p27.
Rosner M; Freilinger A; Hengstschläger M
Mutat Res; 2006 Sep; 613(1):10-6. PubMed ID: 16713332
[TBL] [Abstract][Full Text] [Related]
8. Analysis of 65 tuberous sclerosis complex (TSC) patients by TSC2 DGGE, TSC1/TSC2 MLPA, and TSC1 long-range PCR sequencing, and report of 28 novel mutations.
Rendtorff ND; Bjerregaard B; Frödin M; Kjaergaard S; Hove H; Skovby F; Brøndum-Nielsen K; Schwartz M;
Hum Mutat; 2005 Oct; 26(4):374-83. PubMed ID: 16114042
[TBL] [Abstract][Full Text] [Related]
9. Protein levels of alpha1-tubulin, protein disulfide isomerase, tropomyosins and vimentin are regulated by the tuberous sclerosis gene products.
Hengstschläger M; Rosner M; Fountoulakis M; Oh JE; Lubec G
Cancer Lett; 2004 Jul; 210(2):219-26. PubMed ID: 15183538
[TBL] [Abstract][Full Text] [Related]
10. Antisense suppression of TSC1 gene product, hamartin, enhances neurite outgrowth in NGF-treated PC12h cells.
Floricel F; Higaki K; Maki H; Nanba E; Ninomiya H; Ohno K
Brain Dev; 2007 Sep; 29(8):502-9. PubMed ID: 17376623
[TBL] [Abstract][Full Text] [Related]
11. Mutational analysis of TSC1 and TSC2 in Korean patients with tuberous sclerosis complex.
Choi JE; Chae JH; Hwang YS; Kim KJ
Brain Dev; 2006 Aug; 28(7):440-6. PubMed ID: 16554133
[TBL] [Abstract][Full Text] [Related]
12. Mutation screening of the entire coding regions of the TSC1 and the TSC2 gene with the protein truncation test (PTT) identifies frequent splicing defects.
Mayer K; Ballhausen W; Rott HD
Hum Mutat; 1999; 14(5):401-11. PubMed ID: 10533066
[TBL] [Abstract][Full Text] [Related]
13. Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis.
Niida Y; Lawrence-Smith N; Banwell A; Hammer E; Lewis J; Beauchamp RL; Sims K; Ramesh V; Ozelius L
Hum Mutat; 1999; 14(5):412-22. PubMed ID: 10533067
[TBL] [Abstract][Full Text] [Related]
14. Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/- cells.
Uhlmann EJ; Apicelli AJ; Baldwin RL; Burke SP; Bajenaru ML; Onda H; Kwiatkowski D; Gutmann DH
Oncogene; 2002 Jun; 21(25):4050-9. PubMed ID: 12037687
[TBL] [Abstract][Full Text] [Related]
15. Molecular and clinical analyses of 84 patients with tuberous sclerosis complex.
Hung CC; Su YN; Chien SC; Liou HH; Chen CC; Chen PC; Hsieh CJ; Chen CP; Lee WT; Lin WL; Lee CN
BMC Med Genet; 2006 Sep; 7():72. PubMed ID: 16981987
[TBL] [Abstract][Full Text] [Related]
16. The cell cycle and tuberous sclerosis.
Hengstschläger M; Rosner M
Prog Cell Cycle Res; 2003; 5():43-8. PubMed ID: 14593699
[TBL] [Abstract][Full Text] [Related]
17. Tuberous sclerosis in a 19-week fetus: immunohistochemical and molecular study of hamartin and tuberin.
Wei J; Li P; Chiriboga L; Mizuguchi M; Yee H; Miller DC; Greco MA
Pediatr Dev Pathol; 2002; 5(5):448-64. PubMed ID: 12202993
[TBL] [Abstract][Full Text] [Related]
18. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.
Astrinidis A; Henske EP
Oncogene; 2005 Nov; 24(50):7475-81. PubMed ID: 16288294
[TBL] [Abstract][Full Text] [Related]
19. Novel TSC2 mutations and decreased expression of tuberin in cultured tumor cells with an insertion mutation.
Feng JH; Yamamoto T; Nanba E; Ninomiya H; Oka A; Ohno K
Hum Mutat; 2004 Apr; 23(4):397. PubMed ID: 15024740
[TBL] [Abstract][Full Text] [Related]
20. The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.
Nobukini T; Thomas G
Novartis Found Symp; 2004; 262():148-54; discussion 154-9, 265-8. PubMed ID: 15562827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
